.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer

EP. 1: Dr. Melosky on the Use of Lurbinectedin in SCLC

August 16th 2022

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

EP. 2: Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

August 16th 2022

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

EP. 3: Dr. Florez (Duma) on Nihilism in SCLC

August 17th 2022

Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.

EP. 4: Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer

October 7th 2022

In a recent OncLive® Scientific Interchange moderated by David R. Gandara, MD, experts discussed the prevalence and pathobiology of SCLC cases in their practices; the role of surgery, radiation, prophylactic cranial irradiation (PCI), and systemic therapy in LS-SCLC; and optimal systemic approaches for ES-SCLC in the first-line and relapsed settings.